Developmental pharmacokinetics of mezlocillin in 4 newborn infants. 1988

G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
Department of Pharmaceutics, School of Pharmacy, State University of New York, Buffalo.

The disposition of mezlocillin was evaluated in 4 newborn infants in a sequential two-phase study at postnatal ages of 1 day and 8 or 10 days. Renal function was estimated by creatinine clearance (CLCR) and pharmacokinetic parameters of mezlocillin was were determined from serum concentrations and urinary excretion rates. All weight-normalized mezlocillin clearances (total, renal, and nonrenal) and CLCR were less than adult values, but increased after 8 or 10 days of mezlocillin therapy and postnatal development. The volume of distribution at steady state did not significantly change throughout this period, and approximated the expanded extracellular fluid volume typically found in neonates. The elimination half-lives were substantially shorter by phase II of the study. Both renal and nonrenal elimination processes were enhanced by 1 week of postnatal development even though body weight did not increase. Mezlocillin disposition in neonates is thus affected by body weight, gestational age, and postnatal age.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008802 Mezlocillin Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. Bay-f 1353,Baypen,Melocin,Meslocillin,Mezlin,Mezlocillin Sodium,Mezlocilline,Bay f 1353,Bayf 1353,Sodium, Mezlocillin
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
May 1984, The Journal of pediatrics,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
May 1984, Antimicrobial agents and chemotherapy,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
January 1982, The Journal of antimicrobial chemotherapy,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
January 1982, The Journal of antimicrobial chemotherapy,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
May 1993, Archives of disease in childhood,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
February 1983, Antimicrobial agents and chemotherapy,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
August 1978, Polski tygodnik lekarski (Warsaw, Poland : 1960),
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
April 1982, Antimicrobial agents and chemotherapy,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
January 1993, Medicina,
G L Jungbluth, and F H Wirth, and T T Rubio, and D M Janicke, and W J Jusko
October 1984, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!